CompletedPhase NA

Adiponectin in Patients With Metabolic Disorders

Adiponectin and Its Role in the Treatment of Patients With Metabolic Disorders

Lead sponsor

Moscow Regional Research and Clinical Institute (MONIKI)

Assets

GLP-1 / incretin class catch-all / Liraglutide / Semaglutide

Listed sites

Recruiting sites

Actual enrollment

130

Study population

MASH / NAFLD / liver fibrosis, Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI 25-39.9

Primary endpoint

•Adiponectin, change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07539584

Org study IDAdipo_0222

Timeline

Milestones

Study start2022-03-01actual

Primary completion2024-04-08actual

Study completion2024-04-08actual

Study first posted2026-04-20actual

Last update posted2026-04-22actual

Assets

Investigational agents

GLP-1 / incretin class catch-all Liraglutide Semaglutide

Who this study enrolls

MASH / NAFLD / liver fibrosisObesity / overweightType 2 diabetes

Who can enroll

Minimum age40 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Written informed consent of the patient to participate in the study

•Glycated hemoglobin level exceeding the target by no more than 1%.

•Age 40 to 65 years inclusive

•Verified diagnosis of MAFLD, according to the criteria of EASL 2020,

•Confirmed diagnosis of type 2 diabetes mellitus

•Body mass index (BMI) 25-39.9 kg/m2

•Refusal to take any dietary supplements

Non-inclusion criteria:

•Chronic alcohol abuse (alcoholic fatty liver disease)

•Insulin-dependent diabetes

•Use of hepatoprotective agents

•High risk of atherosclerotic cardiovascular disease (age > 55 years with coronary, carotid, or lower extremity artery stenosis, or left ventricular hypertrophy)

•Chronic kidney disease

•Chronic heart failure

Exclusion criteria

•Patient withdrawal of consent

•Pregnancy (if applicable)

•Decompensation of diabetes during therapy

•Development of adverse events associated with therapy.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

MASH / liver

Cardiometabolic biomarkers

MASH / liver

1 endpoint

Secondary/protocol endpoint

Change in liver steatosis (CAP)

Time frame:Baseline, 6 months

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint

Primary/protocol endpoint

Change in serum HMW-adiponectin levels

Time frame:Baseline and 6 months

Adiponectin, change

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.